The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Slides:

Advertisements

Similar presentations

N Engl J Med; Volume 373(17): ; October 22, 2015

Advertisements

SQUIRE: Improved Survival With Necitumumab + Gemcitabine/Cisplatin vs Gemcitabine/Cisplatin as First-line Treatment in Patients With Squamous NSCLC Slideset.

Bladder Cancer: A New Era in Treatment

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

The Nurse View: Management of Pancreatic Cancer

Prognosis of younger patients in non-small cell lung cancer

COMPLICATIONS OF IMMUNOTHERAPY IN THE HOSPITALIZED PATIENT Vivek Batra MD, Emma Weaver MD Division of Medical Oncology, Thomas Jefferson University, Philadelphia.

Intervista a Lucio Crinò

The Nurse View.

A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer

The Immune System. The Immune System Adaptive Immune Response.

Clinical Considerations in the Management of EGFR-Mutated Advanced NSCLC.

Advanced NSCLC Without Actionable Mutations

Fundamental Concepts in the Diagnosis of Advanced NSCLC

Assessing the Impact: New Data in T790+ NSCLC

New Patient Journeys in Non-small cell lung cancer

The Nurse View.

Progression After Cancer Immunotherapy in Advanced NSCLC

Introduction to Checkpoint Inhibitors

New Standards of Care in ALK-Translocated Advanced NSCLC

Learning Objectives. A Multidisciplinary Approach in Advanced NSCLC in the Era of Immuno-Oncology.

Determining the Best Treatment Algorithm for Patients With Head and Neck Cancer.

Introduction. For Pulmonologists by Pulmonologists: Diagnosis of NSCLC in an Age of Biomarkers.

Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.

Enhancing Patient Care in Advanced NSCLC Through Clinician-Patient Partnership.

Program Goals. The Role of Chemotherapy in Improving Quality of Life in Advanced NSCLC.

Best Practices in Chronic Myeloid Leukemia by Multidisciplinary Teams

The Nurse View: Best Practices in Multiple Myeloma

Optimizing Management of Advanced Bladder Cancer

SC17.02 Lung Cancer in China: Challenges and Perspectives

More Than Meets the Eye.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Essential Concepts in the Use of Immunotherapies in Bladder Cancer

Immunotherapy for cSCC

How to Effectively Manage Patients With Cutaneous Squamous Cell Carcinoma.

Nurse View: Practice Pearls in Advanced Pancreatic Adenocarcinoma

Background. Advancing the Care of Patients With Moderate to Severe Atopic Dermatitis: A Case-Based Discussion.

Immune Checkpoint Inhibitors in Lung Cancer

Locally Advanced Lung Cancer

Defining Patient-Centered Care: Spotlight on Advanced Non-Small Cell Lung Cancer.

Optimizing Targeted Therapy for HER2-Positive Advanced Breast Cancer: Considerations for Previously Treated Disease.

Management of Advanced Pancreatic Adenocarcinoma

Patient-Centered Management in Advanced Non-Small Cell Lung Cancer

The Influence of the Evolution of First-Line Chemotherapy on Steadily Improving Survival in Advanced Non-Small-Cell Lung Cancer Clinical Trials Krista.

All for One: Multidisciplinary Management in EGFR-Mutated NSCLC

Practical Guidance on the Management of Pan-Negative NSCLC

A Nursing Perspective on Improving Outcomes for Patients With Hemophilia.

Patient and Clinician Perspectives on Preventive Therapy for Migraine

Challenges in LA SCCHN.

Preparing for Checkpoint Inhibitors in Breast Cancer

This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data.

The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer.

Activity Goals. Clinical Considerations in the Use of Immune Checkpoint Inhibitors in Advanced NSCLC.

Quality Improvement and Molecular Profiling in Advanced Non-Small Cell Lung Cancer.

Japanese Lung Cancer Registry Study: First Prospective Enrollment of a Large Number of Surgical and Nonsurgical Cases in 2002 Noriyoshi Sawabata, MD,

Targeting the Androgen Pathway: Current Best Practice and Future Directions.

Educational Objectives

Navigating New Treatment Landscapes in HR+ HER2-Negative Advanced Breast Cancer.

Checkpoint Inhibitors in First-Line Advanced NSCLC

A Dose Finding Study of Weekly and Every-3-Week nab-Paclitaxel Followed by Carboplatin as First-Line Therapy in Patients with Advanced Non-small Cell.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Clinical Pearls in the Management of Patients With Advanced Non-Small Cell Lung Cancer.

Combining Immunotherapy and Chemotherapy in NSCLC

Using Q-learning Method in Identify Optimal Treatment Regime

Trends in survival from metastatic lung cancer in California,

Treatment Initiation and Selection in Newly Diagnosed CLL

Updates in Best Practices in Non-Small Cell Lung Cancer

Uncovering the Right Sequence

Presentation transcript:

The Nurse View: Best Practices in Advanced Non-Small Cell Lung Cancer

Lung Cancer Incidence and Mortality

Lung Cancer Pathology

Role of the Oncology Nurse

Case 1: Introduction

Case 1 (cont)

Treatment Considerations for Newly Diagnosed Advanced NSCLC

Treatment Considerations for Newly Diagnosed Advanced NSCLC (cont)

Case 1 (cont)

Management of Lung Cancer-Related Symptoms

Palliative and Supportive Care

Palliative Care and Survival

First-Line Treatment for Advanced Nonsquamous NSCLC

First-Line Treatment for Advanced Squamous Cell Carcinoma

Case 1 (cont)

Common Toxicities of Chemotherapy for NSCLC

Common Toxicities of Monoclonal Antibodies

Managing Treatment-Related Toxicities

Case 2: Introduction

Treatment Beyond Progression FDA-Approved Therapies

Case 2 (cont)

Adverse Effects of Immunotherapies

Summary and Conclusions

Abbreviations

Abbreviations